Many of our doctors are constantly vigilant about our developing skeletal related issues. Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of [...]
Men who develop bone metastases have often been viewed as having developed a significant negative change that prognosticates a negative impact on both their quality of life and on their survival. Contradicting this commonly held belief has been some research which has identified a subgroup of men with advanced prostate cancer with bone metastases who [...]
In a presentation at the ASCO Annual Meeting, Dr. Andrew Himelstein, MD, FACP of the Helen F. Graham Cancer Center & Research Institute, presented the results of a trial evaluating Zoledronic Acid (Zometa) at a dosing schedule of every 12 weeks as opposed to the current standard of care of every 4 weeks. The trial included [...]
Analysis of the PREVAIL Trial showed that Enzalutamide (Xtandi) significantly increased overall survival and radiographic progression-free survival compared with placebo in men with prostate cancer who were asymptomatic and minimally symptomatic, chemotherapy-naive and who had metastatic castration-resistant prostate cancer (mCRPC). Now, an additional analysis of the data has shown the effect enzalutamide also has on [...]
Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung). The last few years has seen the development of new drugs that extend the survival of men. Because of these [...]
